2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

More documents

Recommendations

Info

Imported/localized drugs sales ratio,RUBImported/localized drugs salesratio, packages70% 70% 70%56,3%38% 39% 39,5% 31,4%30% 30% 30%43,7%62% 61% 60,5% 68,6%2017 2018 2019 20202017 2018 2019 2020Localized drugsImported drugsLocalized drugsImported drugsSource: DSM GroupSource: DSM GroupBy the type of dispensing, the ratio in 2020 varied in favor of over-the-counter drugs (OTC).Prescription (Rx) drugs currently account for about 67% in monetary terms. But due to thelower price, OTC drugs prevail in physical terms (54.9%).OTC drugs are mainly sold via pharmacies (about 97% in rubles of the general volume of OTCdrugs). In the state segment, on the contrary, Rx-drugs prevail – they account for more than90% of the tender purchases volume.12RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory
OTC/RX drug sales ratio,RUBOTC/RX drug sales ratio,packages64% 64% 67,3% 66,8%43% 44% 44,4% 45,1%36% 36% 32,7% 33,2%2017 2018 2019 2020Rx (prescription drugs)OTC (over-the-counter drugs)Source: DSM Group57% 56% 55,6% 54,9%2017 2018 2019 2020Rx (prescription drugs)OTC (over-the-counter drugs)Source: DSM GroupVital and Essential Drugs (VED) are a list of drugs approved by the Government of theRussian Federation for the purpose of state regulation of drug prices. The share of VEDsslightly exceeds 50% of the total volume of the drug market both in rubles and in physicalterms.VEDs/non-VEDs sales ratio,RUBVEDs/non-VEDs sales ratio,packages51% 51% 50,8% 44,2%49% 49% 48,7% 46,8%49% 49% 49,2% 55,8%51% 51% 51,3% 53,2%2017 2018 2019 20202017 2018 2019 2020VEDsnon-VEDsVEDsnon-VEDsSource: DSM GroupSource: DSM GroupRUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory13
Page 2 and 3: This publication was developed in t
Page 4 and 5: 1.5 Events ........................
Page 6 and 7: 2.42 PHARM-HOLDING ................
Page 8 and 9: 1 PART 1: MARKET RESEARCH1.1 Indust
Page 10 and 11: The Russian pharmaceutical market i
Page 14 and 15: In 2020, the share of original drug
Page 16 and 17: 1.1.2 Commercial segment of the Rus
Page 18 and 19: 1.1.3 Drug reimbursement segmentAcc
Page 20 and 21: 1.1.4 Segment of purchases of drugs
Page 22 and 23: 1.1.5 Dietary supplements segmentAc
Page 24 and 25: The development of the innovative d
Page 26 and 27: Dynamics of pharmaceutical products
Page 28 and 29: § the term of the SPIC has been ex
Page 30 and 31: The Pharma-2030 Strategy elaboratio
Page 32 and 33: presence of viral RNA and antibodie
Page 34 and 35: § training system in the field of
Page 36 and 37: counter external risks (for example
Page 38 and 39: 1.3.2 The Pavlov First Saint Peters
Page 40 and 41: 1.3.3 North-Western State Medical U
Page 42 and 43: 1.3.4 Military Medical Academy name
Page 44 and 45: 1.3.6 Saint-Petersburg State Instit
Page 46 and 47: 1.3.7 Peter the Great St. Petersbur
Page 48 and 49: 1.3.9 Saint-Petersburg Medico-Socia
Page 50 and 51: 1.4.2 Almazov National Medical Rese
Page 52 and 53: 1.4.4 Institute of Cytology RASInst
Page 54 and 55: 1.4.6 Kashkin Research Institute of
Page 56 and 57: 1.4.8 Research Institute of Hygiene
Page 58 and 59: 1.4.10 Saint-Petersburg Pasteur Ins
Page 60 and 61: Contact informationBekhtereva Str.,
Page 62 and 63:
The Institute has Influenza and ARD
Page 64 and 65:
1.4.14 V. M. Gorbatov Federal Resea
Page 66 and 67:
1.5 Events1.5.1 Events calendarDate
Page 68 and 69:
1.5.2.2 Nordic Life Science DaysNor
Page 70 and 71:
1.5.2.4 HealthBIOThe HealthBIO even
Page 72 and 73:
1.5.2.6 BioJapanBioJapan has played
Page 74 and 75:
1.5.2.8 CPhI WorldwideCPhI is an es
Page 76 and 77:
1.5.2.10 INTERPHEX Japan 2021INTERP
Page 78 and 79:
1.5.3.2 IPhEB RussiaIPhEB Russia is
Page 80 and 81:
1.6 Clusters and associations1.6.1
Page 82 and 83:
1.6.3 Cluster of medical, environme
Page 84 and 85:
1.7 Cases and success stories1.7.1
Page 86 and 87:
1.8 Information sources1.8.1 Strate
Page 88 and 89:
§ DSM Group. Analytical report “
Page 90 and 91:
2.2 ALKOR BIOCompany profileThe St.
Page 92 and 93:
2.4 AMBERCompany profileAmber Group
Page 94 and 95:
2.6 AVENACompany profileAvena compa
Page 96 and 97:
2.8 BELKOZINCompany profileBelkozin
Page 98 and 99:
2.10 BIOCADCompany profileBiocad is
Page 100 and 101:
2.12 BIOPHARMOSCompany profileBioPh
Page 102 and 103:
2.14 BIOTECHCompany profileBiotech
Page 104 and 105:
2.16 CYTOMEDCompany profileCytomed
Page 106 and 107:
2.18 EKVUSCompany profile“Ekvus
Page 108 and 109:
2.20 FARMAKOGENCompany profileFarma
Page 110 and 111:
2.22 FRAMEBIOTEKCompany profileFram
Page 112 and 113:
2.24 GEROPHARMCompany profileGeroph
Page 114 and 115:
2.26 GROTEXCompany profileSolopharm
Page 116 and 117:
2.28 HARMSCompany profileHistory of
Page 118 and 119:
2.30 LEKKERCompany profileThe histo
Page 120 and 121:
2.32 NEPHRONCompany profileResearch
Page 122 and 123:
2.34 NIKACompany profileNika Factor
Page 124 and 125:
2.36 PHARM. ASSOCIATION NAMED FOR P
Page 126 and 127:
2.38 PHARMA VAMCompany profilePharm
Page 128 and 129:
2.40 PHARMAKOR PRODUCTIONCompany pr
Page 130 and 131:
2.42 PHARM-HOLDINGCompany profilePh
Page 132 and 133:
2.44 PHARMSYNTHEZCompany profilePha
Page 134 and 135:
2.46 PPDPCompany profileEnterprise
Page 136 and 137:
2.48 RESEARCH INSTITUTE OF INNOVATI
Page 138 and 139:
2.50 SEVERNAIA ZVEZDACompany profil
Page 140 and 141:
2.52 VITAL DEVELOPMENT CORPORATIONC
Page 142 and 143:
For notes142RUSSIAN-FINNISH LIFE SC
Page 144:
144RUSSIAN-FINNISH LIFE SCIENCE IND
show all

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Create successful ePaper yourself

Delete template?

Save as template?